Sky Labs Showcases CART BP pro for Clinical Trial Applications

Sky Labs announced on Tuesday, July 2, 2026, its data platform business at the 9th Digital Biomarkers in Clinical Trials Summit in Basel, Switzerland. The company emphasized the potential utility of its CART BP pro device, a system designed for monitoring high blood pressure, within the context of clinical drug trials.

The initiative aims to continuously collect and analyze patient physiological data, which could provide more precise insights into drug efficacy and safety. Sky Labs CEO Jack Byunghwan Lee stated that the technology allows for the detection and recording of circulatory abnormalities before they become serious.

Industry analysts suggest that such continuous data collection methods could streamline the drug development process, potentially reducing costs. More accurate patient data may assist regulatory bodies in drug approvals and the design of clinical studies.

Founded in 2017, Sky Labs operates with headquarters in Seoul, South Korea, and near Basel, Switzerland. The company has previously received clearance from European and U.S. regulatory authorities for its high-accuracy blood pressure monitor.